semaglutide cv benefit and Cardiovascular Outcomes in Obesity without Diabetes Post hoc analysis of SUSTAIN

doi: 10.1126/science.1222939

If you follow obesity medicine, weight loss drugs, peptide news, semaglutide, Zepbound, Wegovy, Ozempic, Mounjaro, and patient advocacy, this episode is for you

Part XI: Technology Roadmap Next-Generation Molecules and the New Exclusivity Frontier New Modalities, New IP Architectures The pharmaceutical industrys shift toward novel therapeutic modalities, including mRNA therapeutics, siRNA/antisense oligonucleotides, cell and gene therapies, and antibody-drug conjugates (ADCs), is not merely a scientific development

Like many, I was looking for effective ways to manage my health and weight, and the traditional routes felt overwhelming